EP1945218A2 - Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten - Google Patents
Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheitenInfo
- Publication number
- EP1945218A2 EP1945218A2 EP06777198A EP06777198A EP1945218A2 EP 1945218 A2 EP1945218 A2 EP 1945218A2 EP 06777198 A EP06777198 A EP 06777198A EP 06777198 A EP06777198 A EP 06777198A EP 1945218 A2 EP1945218 A2 EP 1945218A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- acute
- treatment
- lung diseases
- compounds
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to the use of compounds of the formulas I-VI for the manufacture of a medicament for the treatment of acute and chronic lung diseases such as the respiratory distress syndrome (acute acute respiratory distress syndrome (ARDS)) and the treatment of COPD ,
- ARDS acute acute respiratory distress syndrome
- COPD COPD
- noxae directly harmful to the lungs may cause ALI or ARDS, respectively.
- an acute lung disease associated with bilateral infiltrates in chest x-ray and severely impaired respiration after exposure to one of the above-mentioned noxae at a ratio of PaCvFiO 2 ⁇ 300 is said to be ALI, at a ratio of PaO 2 : FiO 2 ⁇ 200 from an ARDS.
- the associated mortality is given as more than 50% and thus represents a serious intensive medical illness.
- Pathophysiological findings include diffuse alveolar damage with invasion of neutrophils, macrophages, erythrocytes, hyaline membrane formation, leakage of high-protein edema fluid, and interruption of the alveolar epithelial barrier with pathologically increased permeability. Histologically, after the stage of pulmonary edema formation, there is an acute and chronic inflammatory reaction with a possible transition to fibrosis. Clinically, a drastically deteriorated gas exchange with reduced oxygenation and difficult ventilation through a disturbed ventilation-perfusion distribution. Most ALI / ARDS patients also have moderate pulmonary hypertension with increased pulmonary resistance, which is due to hypoxic vasoconstriction, destruction and obstruction of the pulmonary alveolar endothelium. In some ALI / ARDS patients, this can lead to right heart failure.
- cGMP cyclic guanosine monophosphate
- NO nitric oxide
- GTP guanosine triphosphate
- the soluble guanylate cyclases consist of two subunits and most likely contain heme per heterodimer, which is part of the regulatory center. This is central to the activation mechanism. NO can bind to the iron atom of the heme and thus significantly increase the activity of the enzyme. Heme-free preparations, on the other hand, can not be stimulated by NO. CO is also able to attack the iron central atom of the heme, whereby the stimulation by CO is much better than that by NO.
- guanylate cyclase plays a crucial role in different physiological processes
- the activators of soluble guanylate cyclase according to the invention are particularly suitable for the preparation of pharmaceutical substances / medicaments for lowering pulmonary hypertension.
- the compounds of the formula I have to VI Regarding Improved Pharmacodynamic Properties 1
- they exert pressure-lowering effects in the pulmonary-arterial circulation independently of the endogenous NO produced in the pulmonary circulation.
- the stimulators of soluble guanylate cyclase enhance the effect of the endogenously produced NO and improve gas turnover through selective pulmonary vascular dilation of the ventilated areas, resulting in a reduction of the intrapulmonary shunt with an increase in oxygenation.
- Cigarette smoke causes COPD as exogenous noxa
- Genetic factors such as ⁇ Xi-antitrypsin deficiency or bronchial hyperreactivity play a minor role
- Chronic bronchitis, fibrosing bronchiolitis and the Emphysema are the three pathological features of COPD, which contribute to a progressive and accelerated loss of forced endospasm vitality (FeVi)
- cough and sputum are present for at least 3 months per year for at least two consecutive years.
- dyspnoea occurs, first under stress, later also at rest.
- Pulmonary vascular remodeling in COPD with fntimahyperplasia and medial hypertrophy is associated with chronic hypoxia, nicotine inflammatory stimuli and frequent bacterial exacerbations as well as hyperextension and airways obstruction.
- moderate pulmonary arte- nal pressures greater than 40 mmHg are not uncommon in patients with at least one episode of acute respiratory failure
- inhalative glucocorticoids are used to reduce the frequency of exacerbations and antibiotics in bacterial bronchitis or pneumonia to reduce the so-called dynamic hypnosis Disease can not be significantly influenced by any of the established therapeutic principles.
- Long-term oxygen therapy is recommended if P A O 2 falls below 55 mmHg in respiratory global failure. Consistently applied, this therapy improves the prognosis, but it can not influence the remodeling of all layers of the pulmonary artery walls.
- the soluble guanylate cyclase activators according to the invention are particularly suitable for the production of pharmaceutical substances / medicaments for the reduction of pulmonary hypertension.
- the compounds of the formulas I to VI according to the invention have improved pharmacodynamic properties on the one hand irrespective of the endogenously produced in the pulmonary circulation NO even in severe endothelial damage and advanced disease pressure lowering in the pulmonary-artellen circulation addition strengthen the stimulators of the soluble guanylate cyclase the effect of the endogenously produced NO and thereby improve the gas exchange by a selective pulmonary vascular dilatation of the ventilated areas, which leads to a reduction of the intrapulmonary shunt with an increase in the oxy- gen.
- the present invention is the use of compounds of formulas (I-VI) and their salts, hydrates, hydrates of the salts for the preparation of a medicament for the reduction of pulmonary hypertension.
- Another object of the present invention is the use of compounds of formulas (I-VI) and their salts, hydrates, hydrates of the salts for the manufacture of a medicament for the treatment of acute and chronic lung diseases such as the Respiratory Distress Syndrome [acute lung Injury (ALI ), acute respiratory distress syndrome (ARDS)] and the treatment of COPD.
- ALI acute lung Injury
- ARDS acute respiratory distress syndrome
- An additional embodiment of the present invention comprises the procedure for the prophylaxis and / or reduction of pulmonary hypertension using at least one of the compounds of the formulas (I-VI)
- Another object of the present invention smd drugs containing at least one compound of the invention and at least one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
- the compounds according to the invention can have a systemic and / or local action.
- they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonarily, sal, sublingual, lingual, buccal, rectal, dermal, transdermal (topical), conjunctivae otic or as an implant or stent.
- the compounds according to the invention can be administered in suitable administration forms.
- Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
- a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
- absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
- parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
- Inhalation medicaments including powder inhalers, nebulizers
- nasal drops solutions or sprays
- lingual, sublingual or buccal tablets films / wafers or capsules
- suppositories ear or ophthalmic preparations
- vaginal capsules aqueous suspensions (lotions, shake mixtures)
- lipophilic suspensions ointments
- creams transdermal therapeutic systems (such as patches)
- milk pastes, foams, scattering powders, implants or stents.
- excipients include, but are not limited to, excipients (eg, microcrystalline cellulose, lactose, mannitol), solvents (eg, liquid polyethylene glycols), emulsifiers and dispersing or wetting agents (e.g., sodium dodecyl sulfate, polyoxysorbitanoleate), binders (e.g., polyvinylpyrrolidone), synthetic and natural polymers (e.g.
- excipients eg, microcrystalline cellulose, lactose, mannitol
- solvents eg, liquid polyethylene glycols
- emulsifiers and dispersing or wetting agents e.g., sodium dodecyl sulfate, polyoxysorbitanoleate
- binders e.g., polyvinylpyrrolidone
- synthetic and natural polymers e.g.
- Another object of the present invention are pharmaceutical compositions containing at least one compound of the formula (I-VI) according to the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
- the formulations may contain from 0.1% to 99% active ingredient according to the procedure, suitably 25-95% for tablets and capsules and 1-50% for liquid formulations, ie the active ingredient should be present in sufficient amounts. to achieve the specified dosage margin.
- mice were treated for 10 days with 300 ppm of Compound (IV) in the feed. At the end of the experiment, the mice were sacrificed and the lungs isolated. The histological processing and evaluation were carried out as in the above-mentioned publication. Compared with the hypoxia control animals, the non-muscularized and partially-muscularized fraction of the pulmonary vessels is significantly reduced in the mice treated with compound (IV) (FIG. 1).
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005047946A DE102005047946A1 (de) | 2005-10-06 | 2005-10-06 | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
PCT/EP2006/009264 WO2007039155A2 (de) | 2005-10-06 | 2006-09-23 | Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1945218A2 true EP1945218A2 (de) | 2008-07-23 |
Family
ID=37106347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06777198A Withdrawn EP1945218A2 (de) | 2005-10-06 | 2006-09-23 | Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090286781A1 (ja) |
EP (1) | EP1945218A2 (ja) |
JP (1) | JP2009510142A (ja) |
KR (1) | KR20080065283A (ja) |
CN (1) | CN101282727A (ja) |
AU (1) | AU2006299149A1 (ja) |
BR (1) | BRPI0616921A2 (ja) |
CA (1) | CA2624716A1 (ja) |
DE (1) | DE102005047946A1 (ja) |
IL (1) | IL190619A0 (ja) |
RU (1) | RU2417083C2 (ja) |
WO (1) | WO2007039155A2 (ja) |
ZA (1) | ZA200802874B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202008014557U1 (de) | 2008-10-27 | 2009-03-12 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Therapeutische Verwendung |
US20130035340A1 (en) * | 2010-02-05 | 2013-02-07 | Bayer Intellectual Property Gmbh | sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS |
EP2585055A1 (de) * | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
CN102485724B (zh) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代噻吩基吡唑并吡啶类化合物及其医药用途 |
WO2012143510A1 (de) * | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung |
KR102137517B1 (ko) * | 2012-07-20 | 2020-07-24 | 바이엘 파마 악티엔게젤샤프트 | 신규 5-아미노테트라히드로퀴놀린-2-카르복실산 및 그의 용도 |
EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
CN108785309A (zh) * | 2018-04-23 | 2018-11-13 | 周静 | 化合物在制备治疗慢性肺病的药物中的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19834044A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943635A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) * | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
US20050181066A1 (en) * | 2002-04-26 | 2005-08-18 | Altana Pharma Ag | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
GB2395431A (en) * | 2002-11-20 | 2004-05-26 | Northwick Park Inst For Medica | Combination of a metal carbonyl compound and a guanylate cyclase stimulant or stabilizer for the therapeutic delivery of carbon monoxide |
WO2005013691A1 (en) * | 2003-08-04 | 2005-02-17 | Hemocorm Limited | Use of boranocarbonates for the therapeutic delivery of carbon monoxide |
JP2007505142A (ja) * | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
GB0325291D0 (en) * | 2003-10-29 | 2003-12-03 | Pfizer Ltd | Novel combination |
DE10351903A1 (de) * | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
US20050255178A1 (en) * | 2004-02-04 | 2005-11-17 | Bloch Kenneth D | Enhancing the effectiveness of an inhaled therapeutic gas |
JP2008515825A (ja) * | 2004-10-05 | 2008-05-15 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 気管支収縮および肺血管収縮の処置用のグアニル酸シクラーゼ刺激因子および一酸化窒素 |
-
2005
- 2005-10-06 DE DE102005047946A patent/DE102005047946A1/de not_active Withdrawn
-
2006
- 2006-09-23 JP JP2008533900A patent/JP2009510142A/ja active Pending
- 2006-09-23 BR BRPI0616921-0A patent/BRPI0616921A2/pt not_active IP Right Cessation
- 2006-09-23 KR KR1020087010682A patent/KR20080065283A/ko not_active Application Discontinuation
- 2006-09-23 EP EP06777198A patent/EP1945218A2/de not_active Withdrawn
- 2006-09-23 RU RU2008117303/15A patent/RU2417083C2/ru not_active IP Right Cessation
- 2006-09-23 AU AU2006299149A patent/AU2006299149A1/en not_active Abandoned
- 2006-09-23 CA CA002624716A patent/CA2624716A1/en not_active Abandoned
- 2006-09-23 US US12/083,121 patent/US20090286781A1/en not_active Abandoned
- 2006-09-23 WO PCT/EP2006/009264 patent/WO2007039155A2/de active Application Filing
- 2006-09-23 CN CNA2006800373890A patent/CN101282727A/zh active Pending
-
2008
- 2008-04-02 ZA ZA200802874A patent/ZA200802874B/xx unknown
- 2008-04-03 IL IL190619A patent/IL190619A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2007039155A2 * |
Also Published As
Publication number | Publication date |
---|---|
BRPI0616921A2 (pt) | 2011-07-05 |
US20090286781A1 (en) | 2009-11-19 |
WO2007039155A3 (de) | 2007-10-11 |
DE102005047946A1 (de) | 2007-05-03 |
AU2006299149A1 (en) | 2007-04-12 |
JP2009510142A (ja) | 2009-03-12 |
CA2624716A1 (en) | 2007-04-12 |
IL190619A0 (en) | 2008-12-29 |
CN101282727A (zh) | 2008-10-08 |
RU2417083C2 (ru) | 2011-04-27 |
KR20080065283A (ko) | 2008-07-11 |
WO2007039155A2 (de) | 2007-04-12 |
RU2008117303A (ru) | 2009-11-20 |
ZA200802874B (en) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60026855T2 (de) | Synergistische kombination von roflumilast und salmeterol | |
EP1945218A2 (de) | Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von akuten und chronischen lungenkrankheiten | |
KR20010024140A (ko) | 부데소니드 및 포르모테롤에 대한 신규 용도 | |
EP2269647A2 (de) | Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika | |
EP1526870B1 (de) | Kombination von loteprednoletabonat und dfho zur behandlung von atemwegserkrankungen, allergischen erkrankungen, asthma und copd | |
EP0038438B1 (de) | Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel | |
WO2007009589A2 (de) | Verwendung von aktivatoren der löslichen guanylatzyklase zur behandlung von raynaud phänomenen | |
DD267187A5 (de) | Verfahren zur herstellung von mitteln zur bekaempfung des asthma bronchiale und der chonisch obstruktiven bronchitis | |
EP2004149B1 (de) | Leflunomid enthaltende pharmazeutische zusammensetzungen | |
DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
EP2001555A1 (de) | Verwendung von strobilurinen zur behandlung von störungen des eisen-stoffwechsels | |
DE60311702T2 (de) | Behandlung von Flavivirusinfizierungen | |
EP1275638B1 (de) | Kombinationspräparat zur Therapie von immunologischen Erkrankungen | |
DE69904051T2 (de) | Zubereitung enthaltend derivate von phenylaminothiophenessigsäure zur behandlung der akuten respiratorischen insuffizienz (ards) und der akuten respiratorischen insuffizienz bei kindern (irds) | |
EP0334164B1 (de) | Antihypertensives Kombinationspräparat | |
KR101736832B1 (ko) | 디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물 | |
DD283931A5 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen | |
KR20170005539A (ko) | 디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물 | |
DE3901508C2 (de) | Arzneimittel auf der Grundlage eines Wismut enthaltenden Präparats in fester Form | |
DE10310908A1 (de) | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von pulmonaler Hypertonie | |
EP1519730A1 (de) | Neue verwendung von imidazotriazinonen | |
DE2532180A1 (de) | Antihypertonikum | |
JPH05320072A (ja) | 虚血性脳疾患治療薬 | |
DE3316611A1 (de) | Antivirusmittel | |
DE3220598A1 (de) | Lipolytische zusammensetzungen und mittel zur behandlung der fettsucht |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080506 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20080901 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130625 |